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I Introduction
Mood disorders -depression and anxiety -are the fourth-leading cause of life-years lost due to disability worldwide, and the primary cause of loss of health in middle-and high-income countries (Lopez et al., 2006) . The 12-month prevalence rates of, for instance, depression in Western European countries suggest that in any year in time up to 10% of a population suffer from an episode of depression (Greenberg et al., 2003; Thomas and Morris, 2003; Wells et al., 2006) . Prevalence rates have grown steadily (Greenberg et al., 2003; Sobocki et al., 2007; Chang et al., 2012; Goldney et al., 2010) .
Most patients suffer from their symptoms at repeated intervals (e.g. Roy and Schurer, 2013; Rouillon, 2011) . During an acute episode, patients have difficulties to concentrate, are overly tired, lack motivation, and are significantly impaired in mastering daily routines. Such side-effects have been reported to reduce an individual's labor supply (e.g. Stewart et al., 2003) and efficiency while working (e.g. Berndt et al., 1998 Berndt et al., , 2002 . The resulting economic burden of managing mood disorders for society is likely to be large.
As easy-to-use medication became available, many countries, including New Zealand and Australia, have opted to treat mood disorders in a primary care setting to integrate patients better into their communities (Sobocki et al., 2007; Greenberg et al., 2003; Fullerton et al., 2011) . New Zealand's Ministry of Health recommended to general practitioners in its Evidence-based Best Practice Guidelines that depression should be treated with both drug regimes and counseling sessions (New Zealand Guidelines Group, 2008) . For New Zealand, no study exists that calculates the current national government expenditures on managing mood disorders in general practice.
In this study, we fill this gap by using de-identified, patient-record data from general practice 1 consultations of an adult population provided by Compass Health, a Wellington-based primary care service provider, over a period of three years. In contrast to many other studies, which we will review in the next section, we estimate the medical care costs managing these conditions as a proportion of total national expenditures on general practice. We also depart from the general literature by applying coarsened exact matching methods (Ho et al., 2007) to address the potential endogeneity in the experience of mood disorders. Often mood disorders are the direct consequence of the experience of pain-intensive chronic illnesses, which also lead to a high level of health care utilization. Simply summing up all health care costs of individuals diagnosed with mood disorders will therefore overstate their economic burden. Coarsened exact matching methods allow us to carefully separate the medical cost of managing mood disorders from the medical costs caused by co-morbidities.
A crucial advantage of our patient-record data is that we directly observe the clinical diagnoses of mood disorders, and of any other co-morbidity, each service provided to primary-care patients and its price. Knowledge of each service provided allows us to accurately count and calculate each cost component, and therefore to assess the dominant treatment regimes that patients receive. Further, using a sophisticated word-search algorithm, we are able to derive from the GPs' clinical notes for each patient the total days not at work, if a medical certificate was issued, and make statements about the likely cost of lost productivity. Last, the availability of more than half of the total patient population in the area of study enables us to almost exactly match all individuals who suffer from mood disorders with a statistical twin based on a large battery of observable characteristics.
The final purpose of our study is two-fold. On the one hand, we seek to provide a most realistic estimate of the national government expenditures of managing one of the leading causes 2 of life-years lost. Such a number is relevant not only to policy-makers as an economic rationale for advocating higher (or lower) levels of expenditures, but also to treasury representatives to understand the leading contributors to government expenditures. On the other hand, we seek to provide an illustration of the usefulness of coarsened exact matching to calculate a realistic figure of public expenditures when endogeneity of the treatment (in our case mood disorders) is of concern.
II Economic cost of mood disorders
To best of our knowledge no study exists on the economic cost, in terms of national government expenditures, of managing mood disorders for New Zealand. Previous studies have assessed this question from a large-scale perspective for various countries in the OECD (Greenberg et al., 2003; Thomas and Morris, 2003; Cuijpers et al., 2007; Sobocki et al., 2007; Chang et al., 2012) , across the European Union (Sobocki et al., 2006) , and for South Australia (Hawthorne et al., 2003) . The existing studies derive their national estimates of the economic burden of mood disorders through an accounting exercise in which the various cost components -the direct cost incurred through health care utilization and the indirect costs that result from lost productivity -are added up. To put the total costs into perspective, these studies compare the relative contribution of direct and indirect to the overall costs, and present the total costs as a proportion of GDP.
A review of this literature (See Table A .1, Online Appendix) shows that the total economic costs amount to about 1% of GDP in all countries except for South Korea (Chang et al., 2012) and South Australia (Hawthorne et al., 2003) where they represent 0.48% and 2.1% of GDP, respectively. In most studies, indirect costs are estimated to be higher than direct medical costs. At the low end are countries from the European Union for which lost productivity makes up 64% of the total costs (Sobocki et al., 2006) , whereas at the high end are South Korea and England with a share of 95% (Chang et al., 2012; Thomas and Morris, 2003) . In most other studies, the costs due to lost productivity are 2-3 times larger than the costs due to health care utilization (Sobocki et al., 2006; Greenberg et al., 2003; Cuijpers et al., 2007; Hawthorne et al., 2003) .
One reason for the large variation in costs across studies is that the 12-month prevalence rates of depression, which are used as the basis for extrapolating the sample calculations to a nationally representative number, differ widely. For instance, in the US the 12-month prevalence rate is 8.7%, but in South Korea it is only 2.5%. Another reason for the differences in the total cost of depression is the large degree of variation in which cost components are included. Although each of the reviewed studies includes both hospital care and prescription drugs, only five out of the seven studies includes GP consultations.
The studies which have multiple years of data available demonstrate an increase in the economic burden of depression over time, but differ in their conclusions why this may be the case. Greenberg et al. (2003) found that in the US an increase of total costs by 7% between 1990 and 2000 is mainly driven by an increase in the demand for prescription drugs (452%) and out-patient services (47%). In contrast, Sobocki et al. (2007) explained the 100% increase of the economic burden of depression/anxiety in Sweden that was observed between 1995 and 2007 with an increase of indirect costs by more than 130%.
None of the reviewed studies net out from the total cost the costs attributed to illnesses that coincide or cause depression such as the experience of chronic pain (Eaton, 2002; Frassure-Smith and Lesperence, 1995; Massie, 2004) or other chronic illnesses. In such a scenario, the total costs attributed to mood disorders are likely to be overestimated.
III Data
In this study we use clinical patient-record data obtained from primary care consultations in New Zealand to calculate the net medical and productivity-related cost of mood disorders. The data are made available by Compass Health which is a non-profit umbrella organization that provides quality management support services to general practitioners and collects data for two Funding to these providers is based on the number of enrolled patients.
Compass Health manages 101 general practices that represent 88% of almost half a million patients registered with a primary health-care provider in this area. In exchange for reimbursement, primary health-care providers are contractually obliged to supply Compass Health with utilization data. Such information include the type and total number of services and referrals provided, the prices charged for the service, and patient details.
We acquired special permission to extract the clinical data (diagnosis and clinical notes) from general practices. In total, 50 practices, representing 56.5% of all patients managed by Compass Health, agreed to participate in this study. Participating practices did not differ in size and location Patients were classified as suffering from depression or anxiety if they were diagnosed with depression or anxiety, and/or were prescribed anti-depressant/anti-anxiety medication in any of the three years of data available. We excluded all patients who were diagnosed with any another mental health condition. Diagnosis of depression/anxiety is based on the relevant Read Codes, the most widely used diagnosis classification system in New Zealand general practice (De Lusignan, 2005) . As GPs often refrain from assigning a Read Code to a diagnosis, we complement our definition with the prescription of antidepressants, in particular selective serotonin re-uptake inhibitors.
1 Currently, 10% of New Zealand's population has been reported to having been prescribed antidepressants since 2006 (Exeter et al., 2009 ), a number which roughly coincides with the average 12-month prevalence rate (survey based) of depression and anxiety (Wells et al., 2006) .
We constructed a measure for the total costs per patient per year by summing the following components:
where C it represents the total costs expressed in New Zealand dollars (referred to as NZ$) priceadjusted to the second quarter of 2012, i and t refer to the individual and year, respectively. The individual cost components are the total number of: (1) We measure the cost of absenteeism (AW it × Wage i ) as the number of days off work for which a medical certificate is required multiplied by an individual's daily labor-market income.
The GP certified days off work are used as a proxy for the actual number of days taken off work in any year. Under New Zealand law employers are able to ask for proof of sickness or injury at any time once an employee takes sick leave, but employers are not required to do so. We extracted the time interval for which the days off work were certified with the help of a natural-languageprocessing algorithm to identify the correct number of days. Once we obtained for each patient the total annual number of days off work, we conducted an extensive manual check to ensure the computed days off work matched the actual days off work written in the medical certificate.
As we do not know a patient's actual labor-market income, we use as proxy the median income of the smallest geographic area in which the individual resides (Meshblock). 2 A daily pay rate is calculated by dividing the Meshblock's median income by the total number of working days in a full year. Our method of estimating income represents a significant improvement over Hawthorne et al. (2003) , which use a state average proxy, or Thomas and Morris (2003) and Cuijpers et al. (2007) , which use national average income data stratified by age and gender.
IV Empirical methods
To estimate the treatment effect of depression and anxiety (DA i ) on the total medical and productivityrelated cost C it , we specify the following model:
where i refers to patient i observed in time period t = 2010, 2011, 2012. The constant α measures the average costs in the sample. DA i is a dummy variable that takes the value of 1 if the individual belongs to the treatment group (depression/anxiety), and 0 otherwise, and β measures the treatment effect of depression/anxiety. The vector X it captures all control variables for which the sample characteristics differ between treatment and control group. All remaining variations in costs are captured by individual-specific heterogeneity (µ i ) and time-period-specific shocks (η it ). This model is estimated with generalized least squares allowing for random effects. Assuming conditional independence and correct functional form, β estimates the causal effect of depression/anxiety on total costs.
We complement the regression analysis by employing coarsened exact and conventional matching methods. Matching estimators generally have the advantage that they force the analyst to be transparent about the effective balance of covariates between treatment and control group. Their semi-parametric nature also avoids the potential misspecification of the conditional mean of the outcome of interest, and the arbitrary specification of impact heterogeneity. In small samples matching estimators may lead to a loss of efficiency (See Imbens, 2004) .
Coarsened exact matching estimators, in addition, have the advantage that they do not require an ex ante fix of the number of matched units. They control for the number of matches by setting the tuning parameters (Iacus et al., 2011; Ho et al., 2007) . The estimator works best in a data scenario in which all or most covariates are discrete, which is the case in our dataset. In a first step, we find a perfect statistical twin for as many members in the treatment group as possible based on the original, categorical data. In a second step, we broaden the category of some control variable (e.g. age) and then find a perfect match for those observations which could not be matched in the first step using the coarsened categories. We repeat this exercise of coarsening the data until we have found a statistical twin for all members in the treatment group. We refer to each step in which we coarsen the data as matching generation. Gender, age, and ethnicity are variables that are unaffected by the treatment; economic deprivation of the neighborhood is a fixed characteristic of the area in which the individual resides; little evidence exists in the literature that depression/anxiety causes any of the nine listed chronic diseases, although evidence exists on the effect of chronic illnesses on the onset of depression (Eaton, 2002; Frassure-Smith and Lesperence, 1995; Massie, 2004 ).
If we cannot find an exact match based on the above criteria (which we will refer to as generation 1), we alter the matching algorithm. 6 For 66% of all cases (generation 1), we found a perfect match. When relaxing the continuous measure of age into a five-year interval (generation 2), we exactly matched another 13% of the sample. When reducing the 21 categories of ethnicity to nine broader categories (see level 1 defined by Statistics New Zealand), we were able to exactly match another 3.4% of the sample successfully (generation 3). For the remaining 17.6% (generation 4 and 5), we coarsened the data more dramatically (ten-year age intervals, number of co-morbidities in-stead of distinct categories, and removing ethnicity from the algorithm). In the case of matching generation 1, 2 and 3 the change in the tuning parameter is minimal, which could be tolerated as small measurement error (See Iacus et al., 2011, p. 348) . For these three generations, we calculate the average treatment effect on the treated (Ā T T t ) in any particular year (t) as the average difference in total cost between patients diagnosed with, or treated for, depression/anxiety and their statistical twin. Standard errors are calculated using the delta method. The treatment effect is interpreted as the average excess cost of depression/anxiety incurred in the primary care sector and due to lost productivity. When using the sample that includes all five matching generations, we use a regression approach in which we control for the variables that were coarsened into broader categories.
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For comparison, we also construct the ATTs using kernel density and nearest-neighbour matching estimators (For an overview Imbens, 2004) . The nearest-neighbour estimator is constructed with one match per observation (without replacement), and we choose the match with the shortest distance between treatment-group and control-group unit. In the case of the kerneldensity estimator, we construct a weighted average of the outcomes of all non-treated units where the weight given to each non-treated unit depends on the closeness to the treated unit. Only units with common support are matched, which is the same assumption made in the coarsened exact matching estimator. We alert that there is no statistically significant difference in ATTs when additionally controlling for the covariates in the full sample relative to calculating the raw mean difference. Alternatively, one can use standard matching estimators on the pruned data as employed in Jones et al. (2011) . We attempted both regression and matching approaches on the pruned data and obtained almost identical results (available upon request). 8 We use the the ado program "psmatch2" written by Edwin Leuven and Barbara Sianesi.
Finally, we use the above estimates to calculate the total cost of depression and anxiety to New Zealand's economy (CDA, see Eq. (3)). We obtain the cost ratio between treated and control group (based on the most conservative figure obtained from matching generation 1) and a nationally representative prevalence rate of depression and anxiety:
where P D is the probability of depression/anxiety in the population, R CDA is the ratio of the cost of depression/anxiety over the cost of the statistical twins, and C is the total expenditure on GP services in New Zealand for the reference period. We derive the population prevalence rate of depression and anxiety P D by adjusting the prevalence rate obtained from our sample of lower North Island patients with population weights. These population weights are derived from Statistics New Zealand Census data (2006) on age, gender, and ethnicity.
V Results
Our estimation sample consists of 111,575 out of 247,447 eligible patients. We excluded patients who are less than 18 years of age (> 50% of sample), who do not have complete data over three years (2%), and who suffered from alcoholism or a psychotic illness (3%). In total, the sample includes 26,889 individuals who are diagnosed to suffer from either depression or anxiety or both. The three-year prevalence rate of depression/anxiety in this clinical sample is therefore 24%, which lies within the life-time prevalence rates of depression (16%) and anxiety (25%) reported in 3) ), the average cost of mood disorders is reduced by 14% to NZ$372 (SE 4.9).
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The included variables in Model (3) explain 18% of the variation in the medical costs per patient. The average cost of mood disorders are large both in absolute and relative terms. Patients who were identified with depression or anxiety cost per year $372 more than patients without mood disorders, ceteris paribus. This is the third highest cost among all other major illnesses considered. Only patients with diabetes ($549) or cardiovascular disease ($395) incur higher costs, and these differences are statistically significant at the 5% level or better.
We now compare the treatment effect of mood disorders with the treatment effects obtained from the various matching methods. Note: Standard errors are calculated with the delta method. a p-value refers to z-statistic on the hypothesis that ATT in this row is statistically the same as ATT of matching generation 1.
We continue our subsequent analysis of the excess counts and costs by expenditure component on the basis of matching generation 1, because it yields the most conservative estimates.
However, the results from all five generations, in conjunction with the standard matching estimates can be used to put bounds around the likely cost estimate. The upper panel of Table 3 re-ports the excess annual count of services by expenditure group. Patients with depression/anxiety, on average, visit a GP four more times per year, obtain five more prescriptions and 2.3 more referrals for pathology tests. They have 0.5 more episodes of days off work that require a medical certificate and spend less than a tenth of a day not working than comparable patients without depression/anxiety. All differences are statistically significant at the 1% level.
The lower panel of Table 3 reports the differences in excess cost of depression/anxiety by expenditure category. By far, the largest component in the total excess burden are prescription drugs (NZ$192), but patients with depression/anxiety also incur NZ$70 more in consultation fees, and NZ$16 more in pathology tests. Lost productivity costs are low, with a difference of NZ$65 per year. Also, the excess cost of counseling sessions is minimal at NZ$15. The latter is not surprising because only a very small group of disadvantaged individuals gets access to these subsidized counseling sessions, and the total number is limited to six sessions per year. Table 3 are the cost and count ratios (column 3) and their standard errors (column 4) that indicate by how much larger were the expenditures of patients with depression/anxiety per year relative to the control group. The cost for consultations are 1.5 times greater for depression/anxiety patients than for their statistical twins, whereas prescription cost and lost productivity cost are 1.8 times higher. In total, the annual costs of patients with depression/anxiety are 1.7 times greater than for patients who are identical to the depression/anxiety group in all other relevant characteristics. All ratios are statistically significant different from 1. Based on the above estimates, we calculated the net direct cost of managing depression and anxiety as a share of national general practice expenditures and as percentage of national GDP.
Also reported in
The cost ratio (excluding lost productivity) is 1.71 whereas the population-weighted prevalence rate of depression is 0.217. For the relevant time period (2012), Crown expenditures on general b The standard errors of the cost and count ratios are bootstrapped with 1000 replications. practice funding were $855 million (New Zealand Treasury, 2012) , while the Accident Compensation Corporation (ACC) spent a total of $64.5 million on General Practice services (GPs, Nurses and Nurse Practitioners under Cost of treatment regulations and Rural GP and PRIME contracts), both expressed in 2012 NZ$. In total, the combined national expenditures on GP services were $920 million. 
VI Conclusion
This is the first study to estimate the direct and indirect cost of managing mood disorders, depression and anxiety, in the New Zealand primary health care system. Using coarsened exact matching estimators, we estimate a conservative lower-bound estimate of the net cost of managing depression and anxiety in general practice as 13.4% of total primary care expenditures, or NZ$366 per patient per year when including lost productivity. More than 82% of these additional costs are incurred by direct, i.e. medical expenditure, while the remaining 18% are incurred by lost productivity. Almost two-thirds of the medical expenditures are driven by prescription drugs, 26% by consultation fees, and 5% by pathology tests. Less than 5% of the total medical costs are incurred through subsidized counseling services, which appears to stand at odds with the large contribution of prescription drugs. Total costs for patients with depression or anxiety are 1.7 times greater than the costs observed for patients that are not suffering from the condition. In combination with our calculation of a three-year prevalence rate of depression/anxiety of 21 percent, this excess cost ratio implies a GP-managed economic burden of mood disorders of at least 0.06% of GDP.
Two important conclusions can be drawn from our analysis: (1) similar to trends in the US (Pratt et al., 2011) , Australia (Stephenson et al., 2013) , and the UK (Spence, 2013) , New Zealand's general practitioners tend to manage depression and anxiety mainly with antidepressant medication, and may even oversubscribe them (Exeter et al., 2009) . Publicly subsidized counseling sessions are only available to a small group of individuals from disadvantaged backgrounds despite the Ministry of Health's guidelines to use both drug regimes and counseling sessions (New Zealand Guidelines Group, 2008) ; (2) the high cost of lost productivity due to depression/anxiety documented in previous studies for other countries may be entirely driven by informal days taken off work, which makes it difficult to accurately measure and monitor the indirect burden of mood disorders.
Our estimates are smaller than estimates of the economic burden of mood disorders in the international literature because we net out the costs incurred through illnesses, age, and socioeconomic disadvantage that correlate strongly with mental health problems. One could argue however that the nature of our data makes it likely to underreport the prevalence of depression and anxiety, which will then lead to a smaller nationally-representative cost calculation. For instance, Cuijpers et al. (2004) found that those suffering minor depression were eight times less likely to utilize a health-care service than their severely depressed counterparts, while less than 50% of individuals with depression seek care (Wittchen et al., 2001; Kessler et al., 2003; Groom et al., 2003) . Nevertheless, our three-year prevalence rate is in line with the 12-month prevalence rates reported in New Zealand's Mental Health Survey (Wells et al., 2006) and in the Dunedin Cohort Study (16.7%) for the same age group (Moffitt et al., 2010 ).
An important limitation of our study is the omission of costs incurred by in-patient service utilization. There is good reason to suggest that this omission will not invalidate our cost calculations. Similar to Australia, in New Zealand mood disorders are predominantly managed by primary care organizations due to a health-care-reform process that started in the mid-1990s. The National Mental Health Strategy was launched in 1994 by the New Zealand Government with the aim to (1) 'decrease the prevalence of mental illness and mental health problems within the community', and (2) 'to increase the health status of and reduce the impact of mental disorders on consumers, their families, care-givers and the general community' (Ministry of Health, 1994) .
Subsequent publications and the establishment of the Mental Health Commission in 1996 helped
to raise awareness about the high prevalence of mental health problems in the population and the need to include family and the community in its management (Mental Health Commission, 2012) .
The Ministry of Health's Evidence-based Best Practice Guideline for the treatment of depression explicitly recommended to refer only the most severe cases of mental health problems, those in imminent danger, to secondary care (New Zealand Guidelines Group, 2008) .
In contrast to New Zealand, the economic burden of mood disorders in Australia is widely cited to be a staggering A$12.6 billion with six million work days lost per year (e.g. Manicavasagar, 2012) . These estimates are referred back to numbers published on the Beyond Blue webpage, a non-governmental organization that seeks to raise awareness about mood disorders. However, to the best of our knowledge we were unable to identify a report that describes the method that resulted in such a large cost calculation. It would be worthwhile replicating our analysis to derive a lower bound of the costs of managing mood disorders in Australia. Lower-bound estimates of these costs are useful for the Australian Treasury and Ministry of Health to monitor and forecast the expenditure burden of a major chronic illness. Note: Treatment group is defined as having been diagnosed with depression or anxiety or having been prescribed with depression/anxiety medication in the last three years. Sample size is reported as person-year observations. DHB stands for District Health Board. p-value refers to the hypothesis test that the mean value of the relevant variable in the treatment group is the same as the mean value of the same variable in the control group. The control group comprises all five matching generations. 
